Carisma Therapeutics Files 8-K on Operations
Ticker: CARM · Form: 8-K · Filed: Apr 1, 2024 · CIK: 1485003
Sentiment: neutral
Topics: operations, financials, filing
Related Tickers: CARM
TL;DR
Carisma Therapeutics (CARM) filed an 8-K on April 1st detailing financial results and operations.
AI Summary
Carisma Therapeutics Inc. filed an 8-K on April 1, 2024, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company was formerly known as Sesen Bio, Inc. and Eleven Biotherapeutics, Inc.
Why It Matters
This 8-K filing provides an update on Carisma Therapeutics' financial status and operational results, which is crucial information for investors and stakeholders to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting operational and financial information, not indicating any immediate or significant new risks.
Key Players & Entities
- Carisma Therapeutics Inc. (company) — Registrant
- Sesen Bio, Inc. (company) — Former company name
- Eleven Biotherapeutics, Inc. (company) — Former company name
- April 1, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for Carisma Therapeutics Inc.?
The primary purpose of this 8-K filing is to report on Carisma Therapeutics Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on April 1, 2024.
What were Carisma Therapeutics Inc.'s previous names?
Carisma Therapeutics Inc. was formerly known as Sesen Bio, Inc. and Eleven Biotherapeutics, Inc.
In which state is Carisma Therapeutics Inc. incorporated?
Carisma Therapeutics Inc. is incorporated in Delaware.
What is the business address of Carisma Therapeutics Inc.?
The business address of Carisma Therapeutics Inc. is 3675 Market Street, Suite 200, Philadelphia, PA 19104.
Filing Stats: 529 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-04-01 08:41:51
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CARM The Nasdaq Stock Mar
Filing Documents
- tm2410111d1_8k.htm (8-K) — 25KB
- tm2410111d1_ex99-1.htm (EX-99.1) — 102KB
- tm2410111d1_ex99-1img001.jpg (GRAPHIC) — 8KB
- 0001104659-24-041568.txt ( ) — 321KB
- carm-20240401.xsd (EX-101.SCH) — 3KB
- carm-20240401_lab.xml (EX-101.LAB) — 33KB
- carm-20240401_pre.xml (EX-101.PRE) — 22KB
- tm2410111d1_8k_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On April 1, 2024, Carisma Therapeutics Inc. (the "Company") announced its financial results for the quarter and year ended December 31, 2023. The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release issued by Carisma Therapeutics Inc. on April 1, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARISMA THERAPEUTICS INC. By: /s/ Steven Kelly Date: April 1, 2024 Steven Kelly President and Chief Executive Officer